News

A new program aims to replace a daily HBV drug with once-monthly—or even quarterly—injections for people managing both HIV and HBV.

CLF065, a long-acting, once-weekly GLP-2 receptor agonist, advances in two inflammatory bowel disease indications. The studies aim to bring a regenerative treatment option to patients living with IBD, who currently have few therapies that repair the damaged intestinal lining at the root of their disease.

Partnering to speed up the discovery of new malaria drugs that target parasite cytoskeletal pathways, with a focus on global access and affordability.

A new platform developed at Scripps Research enables fast, scalable protein evolution—opening the door to new therapies and diagnostics, and to predicting resistance mutations across many disease areas.

Study led by Scripps Research, Texas A&M and additional institutions highlights that the world’s deadliest infectious disease needs novel, effective antibiotics.

First-of-its-kind 1,000-patient clinical study will use RNA-based stool and saliva tests to detect colon polyps — early warning signs of colorectal cancer — before they become cancerous.Study aims to enhance colorectal cancer prevention by identifying polyp molecular signals, offering improved sensitivity over at-home DNA tests, which have limited ability to detect precancerous lesions.

CLBR001 + ABBV-461 is a novel, investigational, two-part, switchable chimeric antigen T cell (sCAR-T) immunotherapy designed to treat solid tumors.

Innovative cellular therapy has potential to treat patients with lupus, systemic sclerosis, myositis and RA without chemotherapy-induced immune suppression.

Calibr-Skaggs’ long-acting injectable (LAI) platform transforms oral malaria treatment atovaquone, aiming for protection from malaria for three months.

CMR316 is a once-weekly inhaled, lung-targeted drug designed to precisely expand lung stem cells and regenerate damaged lung tissue. 

Scientists at Scripps Research and its drug discovery arm, Calibr-Skaggs, develop first-in-class small molecules to repair damaged tissues of the heart, lungs, joints, and more.  

A new study from Scripps Research and Calibr-Skaggs scientists provides pharmacological proof of concept for an upcoming phase 1 clinical trial.

Calibr-Skaggs to partner with AbbVie to support discovery of next-generation sCAR-Ts using genetic medicine-based approaches.

The ALSAM Foundation, founded by the Skaggs family, provides lasting gift to Scripps Research’s drug discovery and development arm.

The expanded strategic collaboration will advance several innovative assets across AbbVie’s core therapeutic growth areas including immunology, oncology, neuroscience.

Calibr scientists engineered a cytokine protein that has shown evidence of providing neuroprotective effects to Parkinson’s disease patients.

Calibr transitions investigational compound CLB073 to Gates MRI to advance development.

2022 year-end roundup: Clinical success and consistent funding validate Calibr’s pioneering approach to drug discovery.

Scripps Research and Calibr scientists collaborate to uncover potential therapeutic avenues for metabolic diseases.

Calibr, the drug development arm of Scripps Research, and other collaborators find microglia play a critical role in SMA disease progression.

Calibr has announced encouraging preliminary data from the first nine subjects in a first-in-human Phase 1 clinical trial studying the first switchable CAR-T cell product (CLBR001 + SWI019) for patients with B cell malignancies.

The multidisciplinary center will focus on development of antiviral drugs to combat coronaviruses and other viruses with pandemic potential.

Global collaboration seeks to develop potential novel, direct-acting antiviral treatments for COVID-19.

Two of the first three patients in the lowest dose cohort experienced a complete response to therapy.